Letrozole

Generic Name
Letrozole
Brand Names
Femara, Kisqali Femara Co-pack
Drug Type
Small Molecule
Chemical Formula
C17H11N5
CAS Number
112809-51-5
Unique Ingredient Identifier
7LKK855W8I
Background

Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990. It is a third generation aromatase inhibitor like exemestane and anastrozole, meaning it does not significantly affect cortisol, aldosterone, and thyroxine.

Letrozole was granted FDA approval on 25 July 1997.

Indication

Letrozole is indicated to treat postmenopausal women with hormone receptor (HR) positive early breast cancer, postmenopausal women with early breast cancer who have periviously been treated with tamoxifen, and postmenopausal women with HR+ or unknown advanced breast cancer. Letrozole, given with ribociclib, is indicated to treat pre, peri, and postmenopausal...

Associated Conditions
Advanced Breast Cancer, Anovulatory cycle, Epithelial Ovarian Cancer, HR+, HER2-, Advanced Breast Cancer, Stage I Breast Cancer, Metastatic HR + HER2 - breast cancer
Associated Therapies
-
Clinical Trials
Related News

A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.

First Posted Date
2019-04-08
Last Posted Date
2023-11-22
Lead Sponsor
St Vincent's Hospital
Target Recruit Count
200
Registration Number
NCT03906669
Locations
🇦🇺

St Vincent's Hospital, Sydney, New South Wales, Australia

PersonaLized neoAdjuvant Strategy ER Positive and HER2 Negative Breast Cancer TO Increase BCS Rate

Phase 2
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Leuprorelin acetate
Drug: Letrozole
Genetic: MammaPrint
First Posted Date
2019-04-03
Last Posted Date
2024-07-31
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
122
Registration Number
NCT03900637
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

Phase 1
Active, not recruiting
Conditions
Breast Neoplasm Female
Interventions
Drug: Venetoclax
Drug: Palbociclib
Drug: Letrozole
First Posted Date
2019-04-03
Last Posted Date
2024-11-07
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Target Recruit Count
17
Registration Number
NCT03900884
Locations
🇦🇺

Royal Melbourne Hospital, Melbourne, Victoria, Australia

🇦🇺

Austin Health, Melbourne, Victoria, Australia

🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

First Posted Date
2019-03-19
Last Posted Date
2023-03-07
Lead Sponsor
University of Chicago
Target Recruit Count
60
Registration Number
NCT03879577
Locations
🇳🇬

University College Hospital, Ibadan, Nigeria, Ibadan, Nigeria

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

First Posted Date
2019-01-30
Last Posted Date
2024-11-27
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
376
Registration Number
NCT03822468
Locations
🇺🇸

Southern Cancer Center PC, Mobile, Alabama, United States

🇺🇸

Rocky Mountain Cancer Centers, Longmont, Colorado, United States

🇺🇸

Nebraska Cancer Specialists, Omaha, Nebraska, United States

and more 12 locations

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

First Posted Date
2018-12-13
Last Posted Date
2024-04-19
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
15
Registration Number
NCT03774472
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

Phase 1
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Dalpiciclib
Drug: Pyrotinib
Drug: Letrozole
Drug: Fulvestrant
First Posted Date
2018-12-11
Last Posted Date
2023-03-07
Lead Sponsor
Fudan University
Target Recruit Count
59
Registration Number
NCT03772353
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

Phase 2
Active, not recruiting
Conditions
Breast Cancer Female
Interventions
Drug: Letrozole
First Posted Date
2018-11-20
Last Posted Date
2024-03-04
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
61
Registration Number
NCT03747042
Locations
🇺🇸

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

First Posted Date
2018-10-01
Last Posted Date
2023-11-15
Lead Sponsor
Emory University
Target Recruit Count
38
Registration Number
NCT03691493
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

🇺🇸

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States

and more 7 locations

RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer

First Posted Date
2018-09-18
Last Posted Date
2024-11-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
130
Registration Number
NCT03675893
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy